Wang Ya1, Cheryl Reifer, Larry E Miller. 1. Department of Gynecology, Yuyao/Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract
OBJECTIVE: We assessed the effectiveness of vaginal probiotic capsules for recurrent bacterial vaginosis (BV) prevention. STUDY DESIGN:One hundred twenty healthy Chinese women with a history of recurrent BV were assigned randomly to daily vaginal prophylaxis with 1 capsule (Probaclac Vaginal; Nicar Laboratories, Inc, Blainville, Quebec, Canada) that contained 8 billion colony-forming units of Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus (n = 58 women) or 1 placebo capsule (n = 62 women) for 7 days on, 7 days off, and 7 days on. RESULTS:Probiotic prophylaxis resulted in lower recurrence rates for BV (15.8% [9/57 women] vs 45.0% [27/60 women]; P < .001) and Gardnerella vaginalis incidence through 2 months (3.5% [2/57 women] vs 18.3% [11/60 women]; P = .02). Between the 2- and 11-month follow-up period, women who received probiotics reported a lower incidence of BV and G vaginalis. Aside from vaginal discharge and malodor, no adverse events were reported in either study group. CONCLUSION: Short-term probiotic prophylaxis is well tolerated and reduces BV recurrence and G vaginalis risk through 11 months after treatment. Copyright (c) 2010 Mosby, Inc. All rights reserved.
RCT Entities:
OBJECTIVE: We assessed the effectiveness of vaginal probiotic capsules for recurrent bacterial vaginosis (BV) prevention. STUDY DESIGN: One hundred twenty healthy Chinese women with a history of recurrent BV were assigned randomly to daily vaginal prophylaxis with 1 capsule (Probaclac Vaginal; Nicar Laboratories, Inc, Blainville, Quebec, Canada) that contained 8 billion colony-forming units of Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus (n = 58 women) or 1 placebo capsule (n = 62 women) for 7 days on, 7 days off, and 7 days on. RESULTS: Probiotic prophylaxis resulted in lower recurrence rates for BV (15.8% [9/57 women] vs 45.0% [27/60 women]; P < .001) and Gardnerella vaginalis incidence through 2 months (3.5% [2/57 women] vs 18.3% [11/60 women]; P = .02). Between the 2- and 11-month follow-up period, women who received probiotics reported a lower incidence of BV and G vaginalis. Aside from vaginal discharge and malodor, no adverse events were reported in either study group. CONCLUSION: Short-term probiotic prophylaxis is well tolerated and reduces BV recurrence and G vaginalis risk through 11 months after treatment. Copyright (c) 2010 Mosby, Inc. All rights reserved.
Authors: Mershen Govender; Yahya E Choonara; Pradeep Kumar; Lisa C du Toit; Sandy van Vuuren; Viness Pillay Journal: AAPS PharmSciTech Date: 2013-09-25 Impact factor: 3.246
Authors: Manjula Gunawardana; Madeline Mullen; Jennifer Yoo; Paul Webster; John A Moss; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2014-02-03 Impact factor: 5.191
Authors: Maria Cristina Verdenelli; Cinzia Cecchini; Maria Magdalena Coman; Stefania Silvi; Carla Orpianesi; Giuliana Coata; Alberto Cresci; Gian Carlo Di Renzo Journal: Curr Microbiol Date: 2016-06-21 Impact factor: 2.188
Authors: Abdallah A Abdelmaksoud; Vishal N Koparde; Nihar U Sheth; Myrna G Serrano; Abigail L Glascock; Jennifer M Fettweis; Jerome F Strauss; Gregory A Buck; Kimberly K Jefferson Journal: Microbiology Date: 2016-01-08 Impact factor: 2.777
Authors: Abigail Norris Turner; Patricia Carr Reese; Karen S Fields; Julie Anderson; Melissa Ervin; John A Davis; Raina N Fichorova; Mysheika Williams Roberts; Mark A Klebanoff; Rebecca D Jackson Journal: Am J Obstet Gynecol Date: 2014-06-17 Impact factor: 8.661